ABSTRACT
Objective To explore the potential impact of the first wave of COVID-19 pandemic on all cause and cause-specific mortality in Norway.
Design Population based register study.
Setting The Norwegian cause of Death Registry and the National Population Register of Norway.
Participants All recorded deaths in Norway during March to May from 2010 to 2020.
Main outcome measures Rate (per 100 000) of all-cause mortality and causes of death in the EU Shortlist for Causes of Death March to May 2020. The rates were age-standardised and adjusted to a 100% register coverage and compared with a 95% prediction interval (PI) based on corresponding rates for 2010-2019.
Results 113 710 deaths were included, of which 10 226 from 2020. We did not observe any deviation from predicted total mortality. There were fewer than predicted deaths from chronic lower respiratory diseases excluding asthma (11.4, 95% PI 11.8 to 15.2) and from other non-ischemic, non-rheumatic heart diseases (13.9, 95% PI 14.5 to 20.2). The death rates were higher than predicted for Alzheimer’s disease (7.3, 95% PI 5.5 to 7.3) and diabetes mellitus (4.1, 95% PI 2.1 to 3.4).
Conclusions There was no significant difference in the frequency of the major causes of death in the first wave of the 2020 COVID-19 pandemic in Norway. An increase in diabetes mellitus deaths and reduced mortality due to some heart and lung conditions may be linked to infection control measures.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Norwegian Institute for Public Health, to which all authors are affiliated. There was no external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval from the ethics committee or privacy ombudsman for research was neither required nor expedient.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All analyses were performed on aggregated data, we did not have access to directly or indirectly person identifiable data at any time. The main analyses are based on cause of death data that are available from the Norwegian Cause of Death Registry (http://statistikkbank.fhi.no/dar/), a public, open access repository (in Norwegian only). The repository is updated regularly, and late incoming death certificates provide a gradually improving coverage. The analyses in this study are based on data retrieved on December 11, 2020; these data are found in in Supplementary table 3. Data on the number of death certificates submitted electronically are not publicly available, but these will be made available on request. Weekly death statistics from the National Population Register can be accessed via Statistics Norway's webpages (https://www.ssb.no/befolkning/artikler-og-publikasjoner/her-finner-du-ukentlige-tall-pa-antall-dode).
http://statistikkbank.fhi.no/dar/
https://www.ssb.no/befolkning/artikler-og-publikasjoner/her-finner-du-ukentlige-tall-pa-antall-dode